SCHEMBL6637022

SCHEMBL6637022

COc1ccc(Cn2nc(Br)nc2Br)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 2/20 0.45
MAPT P10636 2/20 0.45
ALOX15 P16050 1/20 0.45
CMA1 P23946 1/20 0.45
CNR2 P34972 2/20 0.44
CNR1 P21554 1/20 0.44
NPBWR1 P48145 3/20 0.43
GSK3A P49840 1/20 0.42
GSK3B P49841 1/20 0.42
SIGMAR1 Q99720 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
DCTPP1 Q9H773 1/20 0.40
MCHR1 Q99705 1/20 0.40
PDE8B O95263 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16014473 0.86 PTGS1 (0.44) KDM4EALDH1A1MAPTALOX15CMA1
SCHEMBL24569765 0.84 KDM4E (0.42) KDM4EALDH1A1MAPTALOX15CMA1
SCHEMBL16014514 0.84 MET (0.44) KDM4EALDH1A1MAPTALOX15CMA1
SCHEMBL18723695 0.82 CMA1 (0.44) KDM4EALDH1A1MAPTALOX15CMA1
SCHEMBL30525417 0.82 ALDH1A1 (0.41) KDM4EALDH1A1MAPTALOX15CMA1
SCHEMBL27090143 0.82 CNR1 (0.43) KDM4EALDH1A1MAPTALOX15CMA1
SCHEMBL16014845 0.82 ALDH1A1 (0.41) KDM4EALDH1A1MAPTALOX15CMA1
SCHEMBL31707130 0.82 CMA1 (0.44) KDM4EALDH1A1MAPTALOX15CMA1
SCHEMBL16014823 0.82 KDM4E (0.44) KDM4EALDH1A1MAPTALOX15CMA1
SCHEMBL15606410 0.81 HDAC8 (0.40) KDM4EALDH1A1MAPTALOX15CMA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4655069-A1 PYRIDAZINES AS SARM1 INHIBITORS Disarm Therapeutics, Inc. (US) 2025-12-03 EP disclosed
WO-2025215082-A1 FUSED AZINES FOR THE TREATMENT OF INFLAMMATORY DISEASES GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2025-10-16 WO disclosed
US-12404261-B2 Compounds and compositions for treating conditions associated with cGAS NOVARTIS AG (CH) 2025-09-02 US disclosed
CN-120077046-A Triazole-substituted imidazo [1,2-A ] pyrimidines as CGAS inhibitors 葛兰素史密斯克莱知识产权发展有限公司 2025-05-30 CN disclosed
EP-4526298-A1 PYRAZOLE DERIVATIVES AS STING AGONISTS F. Hoffmann-La Roche AG (CH) 2025-03-26 EP disclosed
US-20250092053-A1 TRIAZOLE-SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AS CGAS INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2025-03-20 US disclosed
US-12247033-B2 Triazole-substituted imidazo[1,2-a]pyrimidines as cGAS inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2025-03-11 US disclosed
US-20250074913-A1 PYRAZOLE DERIVATIVES AS STING AGONISTS HOFFMANN-LA ROCHE INC. (US) 2025-03-06 US disclosed
CN-119212989-A Pyrazole derivatives as STING agonists 豪夫迈·罗氏有限公司 2024-12-27 CN disclosed
WO-2024158775-A1 PYRIDAZINES AS SARM1 INHIBITORS DISARM THERAPEUTICS, INC. (US) 2024-08-02 WO disclosed
WO-2014135483-A1 ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2014-09-12 WO disclosed
US-20140010783-A1 ANTIVIRAL COMPOUNDS HOFFMANN-LA ROCHE INC. 2014-01-09 US disclosed
US-20140010783-A1 ANTIVIRAL COMPOUNDS HOFFMANN-LA ROCHE INC. 2014-01-09 US disclosed
US-20140010783-A1 ANTIVIRAL COMPOUNDS HOFFMANN-LA ROCHE INC. 2014-01-09 US disclosed
WO-2014006066-A1 TRIAZOLE COMPOUNDS AS ANTIVIRALS F. HOFFMANN-LA ROCHE AG (CH) 2014-01-09 WO disclosed
WO-2014006066-A1 TRIAZOLE COMPOUNDS AS ANTIVIRALS F. HOFFMANN-LA ROCHE AG (CH) 2014-01-09 WO disclosed
WO-2013178572-A1 TRIAZOLO COMPOUNDS AS PDE10 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2013-12-05 WO disclosed
WO-2013178572-A1 TRIAZOLO COMPOUNDS AS PDE10 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2013-12-05 WO disclosed
EP-1280806-B1 THIENO 2,3-d]PYRIMIDINEDIONES AND THEIR USE AS PHARMACEUTICALS ASTRAZENECA AB (SE) 2004-08-04 EP disclosed
US-20040014634-A1 Thieno[2,3-d]pyrimidinediones and their use as pharmaceuticals ASTRAZENECA AB (SE) 2004-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12247033-B2 Triazole-substituted imidazo[1,2-a]pyrimidines as cGAS inhibitors CGAS, SSB, STING1 KDM4E 3036/4885ALDH1A1 2358/4885MAPT 4330/4885
US-12404261-B2 Compounds and compositions for treating conditions associated with cGAS CGAS, TDP1, IAPP KDM4E 4717/4885ALDH1A1 2159/4885MAPT 104/4885
US-20040014634-A1 Thieno[2,3-d]pyrimidinediones and their use as pharmaceuticals DPYD, TYMP, TYMS KDM4E 3523/4885ALDH1A1 236/4885MAPT 3882/4885
US-20250074913-A1 PYRAZOLE DERIVATIVES AS STING AGONISTS STING1, CGAS, MAVS KDM4E 2535/4885ALDH1A1 4593/4885MAPT 4128/4885
US-20250092053-A1 TRIAZOLE-SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AS CGAS INHIBITORS CGAS, SSB, STING1 KDM4E 3036/4885ALDH1A1 2358/4885MAPT 4330/4885
US-20140010783-A1 ANTIVIRAL COMPOUNDS HAVCR2, EIF2AK2, MAVS KDM4E 2720/4885ALDH1A1 222/4885MAPT 4508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.